MannKind Appoints Christine Mundkur to its Board of Directors
November 27 2018 - 9:00AM
MannKind Corporation (Nasdaq: MNKD) today announced that Christine
Mundkur has joined its Board of Directors, effective November 27,
2018. Ms. Mundkur will also serve as a member of the Audit
Committee of the Board. Ms. Mundkur brings 25 years of experience
in the pharmaceutical industry to the MannKind Board.
“Christine brings a tremendous wealth of
experience to our board of directors,” said Kent Kresa, Chairman of
the Board of MannKind Corporation. “Her success with inhalation
products, in particular, will be an invaluable asset to
MannKind. She is a strong leader and team builder with proven
technical and leadership expertise, which we believe will further
strengthen our board and our company.”
Ms. Mundkur most recently served as chief
executive officer and the non-voting chairman of the board of
directors for Impopharma Inc., a developer of complex formulations
focused on inhalation pharmaceutical products. While at
Impopharma, Ms. Mundkur led the transition of the company from a
successful clinical research organization into a generic
pharmaceutical inhalation development company. Her work included
the internal development and filing of Abbreviated New Drug
Applications of spray and inhalation products. Ms. Mundkur
also held leadership positions as president and chief executive
office of the US Division and head of commercial operations for
North America for Sandoz, Inc. Earlier, she served as chief
executive officer of Barr Laboratories, Inc., where she started her
career as quality and regulatory counsel. In addition, Ms. Mundkur
served as a strategic consultant advising several clients on global
pharmaceutical business strategies. Ms. Mundkur holds a J.D. from
the St. Louis University School of Law and received her B.S. degree
in chemistry from St. Louis University.
The addition of Ms. Mundkur brings the total
number of MannKind Board members to eight.
About MannKind
CorporationMannKind Corporation (NASDAQ:MNKD) focuses
on the development and commercialization of inhaled therapeutic
products for patients with diseases such as diabetes and pulmonary
arterial hypertension. MannKind is currently
commercializing Afrezza® (insulin human) Inhalation Powder, the
Company's first FDA-approved product and the only inhaled
rapid-acting mealtime insulin in the United States, where it
is available by prescription from pharmacies
nationwide. MannKind is headquartered in Westlake
Village, California, and has a state-of-the art manufacturing
facility in Danbury, Connecticut. The Company also employs
field sales and medical representatives across the U.S. For further
information, visit www.mannkindcorp.com.
Forward-Looking StatementsThis
press release contains forward-looking statements that involve
risks and uncertainties. Words such as "believes," "anticipates,"
"plans," "expects," "intends," "will," "goal," "potential" and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements are based
upon MannKind's current expectations. Actual results and
the timing of events could differ materially from those anticipated
in such forward-looking statements as a result of various risks and
uncertainties detailed in MannKind's filings with
the SEC, including its annual report on Form 10-K for the year
ended December 31, 2017. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. All forward-looking statements
are qualified in their entirety by this cautionary statement,
and MannKind undertakes no obligation to revise or update
any forward-looking statements to reflect events or circumstances
after the date of this press release.
Company Contact: Rose Alinaya SVP, Investor
Relations 818-661-5000 ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2023 to Sep 2024